Sodium Polystyrene Sulfonate and Heart Failure Risk: A Comparative Study With Calcium Polystyrene Sulfonate
Nephrology · 2025-09 · 30 (9)
DOI: 10.1111/nep.70117 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Nephrology, online erschienen am 04.09.2025. Verfasst von Takashin Nakayama und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Metabolism, and Nephrology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Heart Failure, Polystyrenes, Hyperkalemia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Health, Labour and Welfare, Japan, Ministry of Education, Culture, Sports, Science and Technology, Japan, Ministry of Health, Labour and Welfare.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Aim
Sodium polystyrene sulfonate (SPS) is one of the classic potassium‐binding agents that remains commonly used in the treatment of hyperkalaemia. However, the potential concern about its sodium load has not been fully investigated. In this study, we evaluated the association between SPS initiation and heart failure (HF), compared with calcium polystyrene sulfonate (CPS).
Methods
This retrospective study enrolled individuals from a nationwide claims database who had been newly prescribed either SPS or CPS between April 2014 and August 2023. The incidence of HF between the two groups was compared using inverse probability of treatment weighting based on the propensity scores.
Results
We analysed 3481 eligible individuals, of whom 478 received SPS and 3003 CPS. Median age (interquartile range) was 78 (71–83) years, 2160 (62%) were male, and median estimated glomerular filtration rate was 47.0 (32.1–63.1) mL/min/1.73 m 2 . Over a median follow‐up of 361 (147–726) days, 709 HF events were documented. Weighted Cox regression analysis demonstrated that SPS users had a higher risk of developing HF (hazard ratio [HR] 1.24; 95% confidence interval [CI] 1.00–1.53). In sub‐group analyses, the association of SPS administration with incident HF was more profound in individuals aged ≥ 78 years (HR 1.37; 95% CI 1.05–1.79) than in those aged < 78 years (HR 1.01; 95% CI 0.69–1.48).
Conclusion
Our analysis of a nationwide real‐world dataset demonstrated that the use of SPS was associated with an increased likelihood of developing HF, suggesting a possible risk related to SPS‐induced sodium loading.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, Metabolism, and Nephrology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
- Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan.
- Department of Advanced Cardiology, The University of Tokyo, Tokyo, Japan.
- Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health, Saitama, Japan.
- Department of Prevention of Diabetes and Lifestyle-Related Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
- Division of Nephrology and Hypertension, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan.
ORCID-Profile: Takashin Nakayama, Akira Okada, Tatsuhiko Azegami
Förderung
- Ministry of Health, Labour and Welfare, Japan
- Ministry of Education, Culture, Sports, Science and Technology, Japan
- Ministry of Health, Labour and Welfare
- Ministry of Education, Culture, Sports, Science and Technology
Zitieren
APA
Nakayama, T., Kaneko, H., Suzuki, Y., Okada, A., Morita, H., Fujiu, K., Takeda, N., Azegami, T., Yokoo, T., Takeda, N., Node, K., Yasunaga, H., Nangaku, M., & Hayashi, K. (2025). Sodium Polystyrene Sulfonate and Heart Failure Risk: A Comparative Study With Calcium Polystyrene Sulfonate. Nephrology, 30(9). https://doi.org/10.1111/nep.70117
Vancouver
Nakayama T, Kaneko H, Suzuki Y, Okada A, Morita H, Fujiu K, et al. Sodium Polystyrene Sulfonate and Heart Failure Risk: A Comparative Study With Calcium Polystyrene Sulfonate. Nephrology. 2025;30(9). doi:10.1111/nep.70117
BibTeX
@article{Nakayama2025,
author = {Nakayama, Takashin and Kaneko, Hidehiro and Suzuki, Yuta and Okada, Akira and Morita, Hiroyuki and Fujiu, Katsuhito and Takeda, Norifumi and Azegami, Tatsuhiko and Yokoo, Takashi and Takeda, Norihiko and Node, Koichi and Yasunaga, Hideo and Nangaku, Masaomi and Hayashi, Kaori},
title = {Sodium Polystyrene Sulfonate and Heart Failure Risk: A Comparative Study With Calcium Polystyrene Sulfonate},
journal = {Nephrology},
year = {2025},
volume = {30},
number = {9},
doi = {10.1111/nep.70117}
}
EUVIMED